1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4 occurred in 52.7% in the tiragolumab arm and 55.7% in the control arm. Evidence Rating Level: 1 (Excellent) Study Rundown: Extensive-stage small-cell lung cancer (ES-SCLC) is currently treated with atezolizumab/carboplatin/etoposide or durvalumab/chemotherapy, however, most patients have